Altimmune to Participate at Two Upcoming Investor Conferences
Altimmune (Nasdaq: ALT) has announced its participation in two upcoming investor conferences. The company will attend the Guggenheim Inaugural Healthcare Innovation Conference in Boston on November 11, 2024, featuring a fireside chat at 11:30 a.m. Eastern Time. Additionally, they will participate in the UBS Global Healthcare Conference in Rancho Palos Verdes on November 13, 2024, with a fireside chat scheduled for 9:30 a.m. Pacific Time and availability for one-on-one meetings. Both sessions will be accessible via webcast through the Events section of Altimmune's website.
Altimmune (Nasdaq: ALT) ha annunciato la sua partecipazione a due prossime conferenze per investitori. L'azienda parteciperà alla Guggenheim Inaugural Healthcare Innovation Conference a Boston l'11 novembre 2024, con una conversazione di approfondimento alle 11:30 ora orientale. Inoltre, parteciperanno alla UBS Global Healthcare Conference a Rancho Palos Verdes il 13 novembre 2024, con una conversazione di approfondimento in programma per le 9:30 ora del Pacifico e disponibilità per incontri individuali. Entrambi gli eventi saranno accessibili tramite webcast nella sezione Eventi del sito web di Altimmune.
Altimmune (Nasdaq: ALT) ha anunciado su participación en dos próximas conferencias para inversores. La compañía asistirá a la Guggenheim Inaugural Healthcare Innovation Conference en Boston el 11 de noviembre de 2024, con una charla programada a las 11:30 a.m. hora del Este. Además, participará en la UBS Global Healthcare Conference en Rancho Palos Verdes el 13 de noviembre de 2024, con una charla programada para las 9:30 a.m. hora del Pacífico y disponibilidad para reuniones uno a uno. Ambas sesiones serán accesibles a través de una transmisión web en la sección de Eventos del sitio web de Altimmune.
Altimmune (Nasdaq: ALT)는 두 개의 예정된 투자자 회의에 참여한다고 발표했습니다. 이 회사는 2024년 11월 11일 보스턴에서 열리는 Guggenheim Inaugural Healthcare Innovation Conference에 참석할 예정이며, 동부 표준시 기준으로 오전 11시 30분에 화상 대화가 진행됩니다. 또 다른 회의로는 2024년 11월 13일 랜초 팔로스 베르데스에서 열리는 UBS Global Healthcare Conference에 참여하며, 태평양 표준시 기준 오전 9시 30분에 화상 대화가 예정되어 있고 일대일 미팅을 위한 시간이 제공됩니다. 두 세션 모두 Altimmune 웹사이트의 이벤트 섹션을 통해 웹캐스트로 접근할 수 있습니다.
Altimmune (Nasdaq: ALT) a annoncé sa participation à deux prochaines conférences pour investisseurs. La société participera à la Guggenheim Inaugural Healthcare Innovation Conference à Boston le 11 novembre 2024, avec une discussion informelle prévue à 11h30, heure de l'Est. De plus, elle participera à la UBS Global Healthcare Conference à Rancho Palos Verdes le 13 novembre 2024, avec une discussion informelle prévue à 9h30, heure du Pacifique, ainsi que des disponibilités pour des réunions individuelles. Les deux sessions seront accessibles par webcast dans la section Événements du site web d'Altimmune.
Altimmune (Nasdaq: ALT) hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. Das Unternehmen wird am 11. November 2024 an der Guggenheim Inaugural Healthcare Innovation Conference in Boston teilnehmen, die um 11:30 Uhr Eastern Time mit einem informellen Gespräch beginnt. Darüber hinaus nehmen sie am 13. November 2024 an der UBS Global Healthcare Conference in Rancho Palos Verdes teil, wobei ein informelles Gespräch für 9:30 Uhr Pacific Time angesetzt ist und Gespräche im Einzelgespräch angeboten werden. Beide Sitzungen sind über einen Webcast im Veranstaltungsbereich der Website von Altimmune zugänglich.
- None.
- None.
GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in the following investor conferences:
- Guggenheim Inaugural Healthcare Innovation Conference (Boston, MA)
Monday, November 11, 2024
Fireside Chat at 11:30 a.m. Eastern Time
- UBS Global Healthcare Conference (Rancho Palos Verdes, CA)
Wednesday, November 13, 2024
Available for 1x1 meetings
Fireside Chat at 9:30 a.m. Pacific Time
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Vipin Garg
President and Chief Executive Officer
Phone: 240-654-1450
ir@altimmune.com
Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com
Investor Contacts:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com
This press release was published by a CLEAR® Verified individual.
FAQ
When is Altimmune (ALT) presenting at the Guggenheim Healthcare Conference in 2024?
What time is Altimmune's (ALT) fireside chat at the UBS Global Healthcare Conference 2024?
How can investors access Altimmune's (ALT) conference presentations in November 2024?
